TC
RNAC icon

Truvestments Capital’s Cartesian Therapeutics RNAC Stock Holding History

Truvestments Capital’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10
Closed -$179 – 1128
2024
Q4 		$179 Buy
+10
New +$202 ﹤0.01% 976

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Truvestments Capital's RNAC Position: Q1 2025 in Review

Truvestments Capital sold out of Cartesian Therapeutics (RNAC) in Q1 2025, closing a stake of 10 shares — an estimated $179 sold.

Truvestments Capital first reported a position in RNAC in Q4 2024 and held it in 1 quarter. The position peaked at $179 in Q4 2024. 72 funds tracked by Wall St. Rank hold RNAC as of Q1 2025.

  • Truvestments Capital reported no remaining Cartesian Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Truvestments Capital sold 10 Cartesian Therapeutics shares in Q1 2025, an estimated $179.
  • Truvestments Capital first reported a position in Cartesian Therapeutics in Q4 2024 and held it in 1 quarter.
  • Truvestments Capital's Cartesian Therapeutics position peaked at $179 in Q4 2024.
  • 72 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2025.

Based on Truvestments Capital's 13F filing for Q1 2025, filed 14 May 2025.